Monitoring CML Treatment: Addressing the Issues for the Community Hematologist/Oncologist Hagop M....
-
Upload
gervais-hoover -
Category
Documents
-
view
214 -
download
0
Transcript of Monitoring CML Treatment: Addressing the Issues for the Community Hematologist/Oncologist Hagop M....
Monitoring CML Treatment: Addressing the Issues for the Community Hematologist/Oncologist
Hagop M. Kantarjian, MDChairman; Professor, Department of LeukemiaUniversity of Texas, MD Anderson Cancer CenterHouston, Texas
Jorge E. Cortes, MDChair, CML Section, Division of Cancer MedicineUniversity of Texas, Department of Leukemia, MD Anderson Cancer CenterHouston, Texas
Ronjay Rakkhit, MDOncology ConsultantsHouston, Texas
William S. Velasquez, MDAllopathic & Osteopathic Physicians Internal Medicine Hematology & OncologyHouston, Texas
• It accounts for 0.34% of all cancers, 3.6% of hematologic malignancies, and 0.08% of all cancer mortality.[a]
• 5050 new cases were estimated in the United States in 2009, and 470 people with CML were estimated to die in the same time period.[a]
• From 2003 to 2007, age-adjusted incidence rates of the disease were 2.0 per 100,000 men and 1.1 per 100,000 women.[b]
CML: Epidemiology
a. Jemal A, et al. CA Cancer J Clin. 2009;59:225-249.b. NCI/SEER. Available at: http://seer.cancer.gov/statfacts/html/cmyl.html
• Myeloproliferative disorder of the primitive hematopoietic stem cell[a]
• Arises from a translocation t(9;22)(q34;q11), known as the Philadelphia chromosome[a]
• Resulting bcr-abl1 fusion gene codes for a constitutively active tyrosine kinase[a,b]
CML: Pathophysiology
a. Kantarjian H, et al. Blood. 1993;82:691-703.b. Quintás-Cardama A, Cortés JE. Blood. 2009;113:1619-1630.
• Most cases are diagnosed in the chronic phase (CP).[a]
• Before the advent of imatinib therapy, the median survival was approximately 3-4 years.[b]
• The advent of imatinib changed the natural history of CML.[c]
CML: Advent of Imatinib
a. Faderl S, et al. N Engl J Med. 1999;341:164-172.b. Kantarjian H, et al. Cancer. 2008;113(suppl):1933-1952.c. Weisberg E, et al. Nat Rev Cancer. 2007;7:345-356.
CML: IRIS Trial 5- and 8-Year Follow-up[a]
a. Druker BJ, et al. N Engl J Med. 2003;355:2408-2417.b. Deininger M, et al. ASH 2009. Abstract 1126.
• At 8 years, estimated overall survival was 85%, and 93% when only CML-related deaths were considered.[b]
Appropriate in Patients With Suspected CML at Diagnosis?
Bone Marrow Analysis in the Community Setting
May Provide Information About Additional Chromosomal Abnormalities and Number of Blasts
Appropriate and Important in Patients With Suspected CML at Diagnosis
Bone Marrow Analysis in the Community Setting
Patients With Newly Diagnosed CML-CPNilotinib vs Imatinib: Phase 3 ENESTnd Trial
Larson RA, et al. ASCO 2010. Abstract 6501.
Rate of progression to AP/BC CML •Nilotinib 300 mg BID: 0.7% (P = .006 vs imatinib) •Nilotinib 400 mg BID: 0.4% (P = .003 vs imatinib) •Imatinib 400 mg QD: 4.2%
Response (%)
Nilotinib 300 mg BID
(n = 282)
Nilotinib 400 mg BID
(n = 281)
Imatinib 400 mg QD
(n = 283)MMR• At 12 mo (ITT) 44* 43* 22• At 18 mo (n = 525) 69 63 36• At 24 mo (n = 145) 86 88 48CCyR• At 12 mo (ITT) 80* 78† 65• At 18 mo (n = 442) 99 99 89
*P < .0001 vs imatinib†P < .001 vs imatinib
Patients With Newly Diagnosed CML-CPDasatinib vs Imatinib: Phase 3 DASISION Trial
Kantarjian H, et al. ASCO 2010. LBA6500.
Dasatinib IMn (%) P
CCyR (≥ 20 metaphases)
3 mo 140 (54) 80 (31)
6 mo 189 (73) 154 (59)
12 mo 216 (83) 186 (72) .0011
MMR
3 mo 21 (8) 1 (<1)
6 mo 70 (27) 21 (8)
12 mo 119 (46) 73 (28) < .0001
• Identify patient with suboptimal response early– Do not wait until the patient loses hematologic response
• Intervene early– Optimize dose– Change therapy– Increase probability of good response and long-term
favorable outcome
Frequent MonitoringImportance and Rationale
Patients With Cytogenetic Relapse Typically Respond Better to Second-Generation TKIs Than Patients With Hematologic Relapse.
Imatinib FailureOperational Criteria
Baccarani M, et al. J Clin Oncol. 2009;27:6041-6051.CCA = clonal chromosome abnormalities
Evaluation Time (mo) FailureBaseline NA
3 Less than CHR
6 No CyR (Ph + > 95%)
12 Less than PCyR (Ph + > 35%)
18 Less than CCyR
Any time during treatment Loss of CHR; loss of CCyR; mutations; CCA/PH+
Rarely a First-line Therapy Even in Patients in Accelerated or Blastic Phase or Those Who
Failed to Respond to Imatinib (Except in Patients With T315I Mutation)
Role of Allogeneic Transplant Today